NTZ was associated with a 44% reduction of upper extremity disability (as measured on the 9HPT) compared to placebo (<italic>P</italic>=0.001)</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">1. NTZ reduced the mean number of new/enlarging T2 lesions by 89% compared to placebo<break/>2. NTZ reduced Gd+ lesions by 95% compared to placebo</td><td valign=\"top\" align=\"left\" rowspan=\"1\" colspan=\"1\">Similar to known safety profile above</td></tr></tbody></table>\n"}, "text": "Trial name\tNumber of patients enrolled\tType of patient enrolled\tStudy design\tPrimary outcomes\tSecondary clinical outcomes\tSecondary MRI outcomes\tNotable adverse events\t \tAFFIRM\t942\tRRMS\tRandomized placebocontrolled NTZ 300 mg IV every 4 weeks versus placebo infusion every 4 weeks\t1. NTZ reduced ARR by 68% at 1 year compared to placebo (P<0.001)2. NTZ reduced the risk of sustained disability worsening at 2 years by 42% compared to placebo (P<0.001)\t1. Proportion of relapse-free patients was significantly higher in NTZ group than placebo at 1 year (77% vs 56%, P<0.001) and at 2 years (67% vs 41%, P<0.001)\t1. NTZ reduced the mean number of new/enlarging T2 lesions by 83% compared to placebo over 2 years2. NTZ reduced the mean number of Gd+ lesions by 92% compared to placebo at years 1 and 2\t1. Fatigue2. Allergic reaction3. Hypersensitivity reactions\t \tSENTINEL\t1,171\tRRMS\tRandomized placebo controlledNTZ 300 mg IV every 4 weeks + IFN-beta-1a 30 microg IM weekly (combination therapy) versus IFN-beta-1a 30 microg IM weekly + placebo infusion every 4 weeks\t1. Combination therapy reduced the ARR by 54% at 1 year compared to IFN-beta-1a 30 microg IM + placebo (maintained at 2 years) (P<0.001)2. Combination therapy reduced the risk of sustained disability worsening at 2 years by 24% compared to IFN-beta-1a 30 microg IM + placebo (P=0.02)\t1. Proportion of relapse-free patients was significantly higher in the combination therapy group compared with IFN-beta-1a 30 microg IM + placebo at 2 years (54% vs 32%, P<0.001)2. Risk of relapse was 50% lower with combination therapy (HR 0.50; 95% CI 0.43-0.59; P<0.001)\t1. NTZ + IFN-beta-1a 30 microg IM reduced the mean number of new/enlarging T2 lesions by 83% compared with IFN-beta-1a 30 microg IM + placebo over 2 years2. NTZ + IFN-beta-1a 30 microg IM reduced the mean number of Gd+ lesions by 89% at 2 years compared with IFN-beta-1a 30 microg IM + placebo\t1. Anxiety2. Pharyngitis3. Sinus congestion4. Peripheral edema5. PML (n=2 at the time of publication)\t \tASCEND\t887\tSPMS\tRandomized placebo controlled NTZ 300 mg IV every 4 weeks versus placebo infusion every 4 weeks\t1. No significant difference in disability progression between the NTZ and placebo group (P=0.287)\t1. NTZ was associated with a 44% reduction of upper extremity disability (as measured on the 9HPT) compared to placebo (P=0.001)\t1. NTZ reduced the mean number of new/enlarging T2 lesions by 89% compared to placebo2. NTZ reduced Gd+ lesions by 95% compared to placebo\tSimilar to known safety profile above\t \t", "sentences": [], "annotations": [], "relations": []}, {"offset": 55101, "infons": {"file": "t1-ndt-13-1691.xml", "id": "t1-ndt-13-1691", "section_type": "TABLE", "type": "table_footnote"}, "text": "Abbreviations: MRI, magnetic resonance imaging; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis; IV, intravenous; NTZ, natalizumab; IFN-beta-1a, interferon beta-1a; IM, intramuscular; ARR, annualized relapse rate; CI, confidence interval; 9HPT, 9-hole peg test; Gd+, gadolinium-enhancing; PML, progressive multifocal leukoencephalopathy; HR, hazard ratio.